| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Gustavo Drügg Hahn, Jean-Frédéric LeBlanc, Petra Anna Golovics, Panu Wetwittayakhlang, Abdulrahman Qatomah, Anna Wang, Levon Boodaghians, Jeremy Liu Chen Kiow, Maryam Al Ali, Gary Wild, Waqqas Afif, Alain Bitton, Peter Laszlo Lakatos and Talat Bessissow |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Peter Laszlo Lakatos, AGAF, DSc, FEBG, MD, PhD, Chief Physician, Professor, Division of Gastroenterology, IBD Center, McGill University Health Center, 1650 Ave. Cedar, D7.211, Montreal H3G 1A4, Quebec, Canada. kislakpet99@gmail.com |
| Key Words |
Inflammatory bowel disease; Biologics; Elderly; Efficacy; Safety; Adverse events |
| Core Tip |
Data on the efficacy and side effects of biologic therapies in the elderly inflammatory bowel disease (IBD) population is scant. Our single center study evaluates retrospectively the drug sustainability, effectiveness, and safety of approved biologic therapies in this sensitive population. The major finding of our study was that the drug sustainability and safety of the different biologicals were not significantly different in a large real-world, elderly IBD cohort treated in this single tertiary IBD center. As a consequence, we are still not able to suggest a preferred sequencing order among biologicals. |
| Publish Date |
2022-08-31 11:27 |
| Citation |
Hahn GD, LeBlanc JF, Golovics PA, Wetwittayakhlang P, Qatomah A, Wang A, Boodaghians L, Liu Chen Kiow J, Al Ali M, Wild G, Afif W, Bitton A, Lakatos PL, Bessissow T. Effectiveness, safety, and drug sustainability of biologics in elderly patients with inflammatory bowel disease: A retrospective study. World J Gastroenterol 2022; 28(33): 4823-4833 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i33/4823.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i33.4823 |
